Duloxetine, (+)-(S)-N-Methyl-3-(naphyloxy)-3-(2-thienyl)propylamine, C18H19NOS, M 297,42
Serotonine and norepinephrine reuptake inhibitor (SNRI)
Brand name: Cymbalta™, Yentreve™
Application
Yentreve: women stress urinary incontinence (SUI)
Cymbalta: Treatment of moderate to severe major depressive disorders and diabetic peripheral neuropathy
Contraindications
Duloxetine should not be used in patients with: liver or kidney diseases, epileptic diseases, patients under 18 years.
Interactions
After treatment with MAO-inhibitors, Duloxetine should be taken only after expiration of a 14 days period, in order to avoid an occurrence of the serotonine syndrome.
Adverse Effects
In particular at the beginning nausea, tiredness or sleep disturbances arises. Further on sexual problems are reported. When the setting off from Duloxetin is too fast, fear conditions could arise with a potential higher suicide risk.
